Clinical Trials in Cedarhurst, New York

14 recruiting

Showing 114 of 14 trials

Recruiting
Phase 2

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Major Depressive Disorder
Syndeio Biosciences, Inc164 enrolled34 locationsNCT06547489
Recruiting
Phase 3

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Bipolar DisorderBipolar I DisorderBipolar II Disorder+1 more
Xenon Pharmaceuticals Inc.400 enrolled28 locationsNCT07172516
Recruiting
Phase 2

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

Treatment Resistant Depression (TRD)
Alto Neuroscience178 enrolled48 locationsNCT07553637
Recruiting
Phase 4

A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

Crohn's DiseaseUlcerative Colitis
Takeda400 enrolled98 locationsNCT06581328
Recruiting
Phase 3

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder
Neurocrine Biosciences850 enrolled87 locationsNCT06966401
Recruiting
Phase 3

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder
Neurocrine Biosciences200 enrolled30 locationsNCT06963021
Recruiting
Phase 2

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Major Depressive Disorder
Syndeio Biosciences, Inc164 enrolled32 locationsNCT07115329
Recruiting
Phase 3

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

Schizophrenia
Neurocrine Biosciences800 enrolled53 locationsNCT07114874
Recruiting
Phase 3

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

Schizophrenia
Neurocrine Biosciences560 enrolled17 locationsNCT07227818
Recruiting
Phase 3

Study to Assess the Safety and Effectiveness of NMRA-335140-501

Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled178 locationsNCT06029439
Recruiting
Phase 2

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

Bipolar I or II Disorder
AbbVie200 enrolled49 locationsNCT07220460
Recruiting
Phase 1

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

Obese But Otherwise Healthy Participants
Corbus Pharmaceuticals Inc.252 enrolled15 locationsNCT07310901
Recruiting
Phase 2

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

Type 2 Diabetes Mellitus
Hoffmann-La Roche240 enrolled51 locationsNCT07112872
Recruiting
Phase 3

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

AnxietySocial Anxiety DisorderADHD+1 more
Otsuka Pharmaceutical Development & Commercialization, Inc.308 enrolled47 locationsNCT06973577